Advances in colonic drug delivery

被引:162
作者
Basit, AW [1 ]
机构
[1] Univ London, Sch Pharm, London WC1N 1AX, England
关键词
D O I
10.2165/00003495-200565140-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Targeting drugs and delivery systems to the colonic region of the gastrointestinal tract has received considerable interest in recent years. Scientific endeavour in this area has been driven by the need to better treat local disorders of the colon such as inflammatory bowel disease (ulcerative colitis and Crohn's disease), irritable bowel syndrome and carcinoma. The colon is also receiving significant attention as a portal for the entry of drugs into the systemic circulation. A variety of delivery strategies and systems have been proposed for colonic targeting. These generally rely on the exploitation of one or more of the following gastrointestinal features for their functionality: pH, transit time, pressure or microflora. Coated systems that utilise the pH differential in the gastrointestinal tract and prodrugs that rely on colonic bacteria for release have been commercialised. Both approaches have their own inherent limitations. Many systems in development have progressed no further than the bench, while others are expensive or complex to manufacture, or lack the desired site-specificity. The universal polysaccharide systems appear to be the most promising because of their practicality and exploitation of the most distinctive property of the colon, abundant microflora.
引用
收藏
页码:1991 / 2007
页数:17
相关论文
共 154 条
[51]   Drug delivery to the colon [J].
Fish, NW ;
Bloor, JR .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (11) :1515-1521
[52]   EXPRESSION OF A MULTIDRUG-RESISTANCE GENE IN HUMAN-TUMORS AND TISSUES [J].
FOJO, AT ;
UEDA, K ;
SLAMON, DJ ;
POPLACK, DG ;
GOTTESMAN, MM ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (01) :265-269
[53]  
FOLLONIER N, 1992, STP PHARMA SCI, V2, P141
[54]   Review article: oral, modified-release mesalazine formulations - proprietary versus generic [J].
Forbes, A ;
Cartwright, A ;
Marchant, S ;
McIntyre, P ;
Newton, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (10) :1207-1214
[55]   COLON-SPECIFIC DRUG DELIVERY [J].
FRIEND, DR .
ADVANCED DRUG DELIVERY REVIEWS, 1991, 7 (01) :149-199
[56]   SIGNIFICANCE OF MICROFLORA IN PROTEOLYSIS IN THE COLON [J].
GIBSON, SAW ;
MCFARLAN, C ;
HAY, S ;
MACFARLANE, GT .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1989, 55 (03) :679-683
[57]   CIRCADIAN VARIATION IN GASTRIC-EMPTYING OF MEALS IN HUMANS [J].
GOO, RH ;
MOORE, JG ;
GREENBERG, E ;
ALAZRAKI, NP .
GASTROENTEROLOGY, 1987, 93 (03) :515-518
[58]   Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans [J].
Goto, T ;
Tanida, N ;
Yoshinaga, T ;
Sato, S ;
Ball, DJ ;
Wilding, IR ;
Kobayashi, E ;
Fujimura, A .
JOURNAL OF CONTROLLED RELEASE, 2004, 97 (01) :31-42
[59]   A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development [J].
Gupta, VK ;
Beckert, TE ;
Price, JC .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 213 (1-2) :83-91
[60]   Resistant starch -: a review of the physical properties and biological impact of RS3 [J].
Haralampu, SG .
CARBOHYDRATE POLYMERS, 2000, 41 (03) :285-292